Outlook Therapeutics (OTLK) Return on Capital Employed Growth (1y) (2017 - 2026)
Outlook Therapeutics (OTLK) Return on Capital Employed Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 45.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -785.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1,629.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3,193.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -28.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 399.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -310.00 |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 52,372.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -80,525.00 |
| Dec 31, 2025 | -13,539.00 |
| Sep 30, 2025 | -129,524.00 |
| Jun 30, 2025 | 125,853.00 |
| Mar 31, 2025 | 69,092.00 |
| Dec 31, 2024 | 7,602.00 |
| Sep 30, 2024 | 92,441.00 |
| Jun 30, 2024 | -845,412.00 |
| Mar 31, 2024 | 79,727.00 |
| Dec 31, 2023 | 46,662.00 |
| Sep 30, 2023 | 109,172.00 |
| Jun 30, 2023 | 805,094.00 |
| Mar 31, 2023 | -22,467.00 |
| Dec 31, 2022 | -5,034.00 |
| Sep 30, 2022 | -21,090.00 |
| Jun 30, 2022 | 6,940.00 |
| Mar 31, 2022 | 85,422.00 |
| Dec 31, 2021 | 90,609.00 |
| Sep 30, 2021 | 15,968.00 |
| Jun 30, 2021 | 96,551.00 |